7 results about "Lipocalin" patented technology

The invention provides a method of detecting renal cancer mark- ers in a biological sample from a patient suspected of or to be evaluated for having renal cancer, comprising detecting one or more marker proteins selected from Lipocalin 15, Serum amyloid A1, and Haptoglobin, in the biological sample. The invention further provides a kit suitable for use with the inventive method.

The invention provides an application of lurasidone or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating diabetes individual bone injury healing disorder. The hyperglycemia environment causes excessive secretion of lipocalin-2 (LCN2) by activating a phosphopentose pathway of neutrophil, thereby inhibiting osteogenic differentiation of skeletal stem cells. According to the application of the lurasidone or the pharmaceutically acceptable salt thereof in the preparation of the medicine for preventing and / or treating the diabetic individual bone injury healing disorder, in the application provided by the invention, the lurasidone can specifically inhibit the metabolic pathway and the secretion of LCN2, remodel an immune microenvironment beneficial to repair, and promote the healing of the diabetic individual bone injury. The formation of callus under the condition of diabetes mellitus is obviously accelerated and the mineral density of bone is improved.

The application provides preparation and application of a diagnostic monoclonal antibody for a new epitope of human neutrophil lipocalin (HNL). Two new HNL protein conformation epitopes and one new HNL linear epitope are designed and provided, and an anti-HNL antibody with higher binding affinity and better binding specificity is screened to combine the new epitopes. The anti-HNL antibody of the application can be used for preparation of an HNL detection reagent and kit, and has higher sensitivity and specificity when used for detecting HNL protein in a sample, and can be applied to distinguishing bacterial infection and viral infection.

This invention relates to the field of bioengineering technology, specifically to a method for preparing neutrophil gelatinase-associated lipid transport protein and its antibody. Specifically, using pET23a(+) as the expression vector, the NGAL gene with six His tags fused to its N-terminus under promoter control is introduced into *E. coli* for induced expression. After purification using a Ni Focurose 6FF column and a molecular sieve column, tag-free NGAL protein with a purity ≥95% is obtained. Subsequently, the NGAL protein is used to repeatedly immunize Japanese rabbits, and serum is collected after each immunization. Qualified serum is screened using a two-dimensional agar diffusion assay, and then purified using the aforementioned antigen to prepare an antigen affinity purification column, yielding a highly active NGAL polyclonal antibody. The high-purity recombinant NGAL of this invention not only possesses activity but is also low-cost, not limited by raw materials, and can be mass-produced, possessing potential and wide-ranging application value in clinical and in vitro diagnostics.

The invention discloses a biomarker composition and application thereof, and belongs to the field of biomarker analysis and detection. The invention firstly provides a group of biomarker compositions, wherein the biomarker compositions comprise a Klotho protein and a neutrophil gelatinase associated lipocalin (NGAL); the combined detection biomarker composition can be used for early assessment of the risk of hypertensive disorder in pregnancy complicated with acute kidney injury. When the marker composition is used for predicting the risk of hypertensive disorder in pregnancy complicated with acute kidney injury, the risk of acute kidney injury can be recognized in advance in the early pregnancy stage.

The application belongs to the technical field of biological pigment reconstruction and protein engineering, and particularly relates to a pigment complex based on recombinant macrobrachium rosenbergii lipid carrier protein as well as an in-vitro preparation method and application thereof. The formation of the pigment complex relies on the synergistic stabilization of a key residue network of the recombinant macrobrachium rosenbergii lipid carrier protein, a pigment characteristic end group and phosphatidyl ethanolamine. The application has important scientific significance and industrial value for revealing the protein-pigment-lipid ternary interaction rule, constructing a thermal response color-changing system, expanding the application of protein-based pigment materials and providing a technical basis for color biomimetic construction in food and other systems.

The invention provides preparation and application of a monoclonal antibody for diagnosis aiming at a human neutrophil lipocalin (HNL) neoepitope. Two new HNL protein conformational epitopes and a new HNL linear epitope are designed and provided, and the anti-HNL antibody which is combined with the new epitopes and has higher binding affinity and better binding specificity is obtained through screening. The anti-HNL antibody disclosed by the invention can be used for preparing an HNL detection reagent and a kit, has higher sensitivity and specificity when being used for detecting HNL protein in a sample, and can be applied to distinguishing bacterial infection and virus infection.